🚀 VESALIUS-CV delivers powerful evidence: in high-risk patients without prior MI or stroke, evolocumab significantly reduced 3-point MACE by 25% and 4-point MACE by 19%, with LDL-C lowered to a median of 45 mg/dL.

💡 These results expand the horizon of prevention, showing that deep LDL reduction is both safe and effective in averting first cardiovascular events.

🫀 Strong science. Clear signal. A new chapter in preventive cardiology.

#Cardiology #LDL #Prevention #VESALIUSCV